SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
OFIX reported third quarter 2026 results. The price and volatility reaction is pending.
OFIXearnings

Orthofix Medical Inc. (OFIX) Q3 FY2026 earnings

November 9, 2026 · SharpeIQ Research Desk

Reported results

  • Reported net sales were $207.9 million for the third quarter of 2026, up 1.1% on a reported basis compared to the third quarter of 2025.
  • Pro forma net sales (non-GAAP) were $207.8 million for the third quarter of 2026, representing an increase of 2.3% on a non-GAAP pro forma constant currency basis.
  • Reported net loss was $(6.1) million, or $(0.15) per share, for the third quarter of 2026.
  • GAAP gross margins were 70.5% for the third quarter of 2026.
  • Non-GAAP adjusted gross margin was 70.7% for the third quarter of 2026.
  • Non-GAAP adjusted EBITDA was $26.0 million, or 12.5% of pro forma net sales, for the third quarter of 2026.

Guidance

  • Full-year 2026 net sales are expected to range from $825 million to $830 million.
  • Full-year 2026 non-GAAP adjusted EBITDA is expected to range from $86 million to $88 million.

Notes

Unless otherwise noted, pro forma results exclude the impact of the discontinued M6 product lines.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →